Denali Therapeutics and Royalty Pharma Collaborate on Funding Deal
Denali Therapeutics Inc. (NASDAQ: DNLI) and Royalty Pharma plc (NASDAQ: RPRX) have recently announced a significant synthetic royalty funding agreement worth $275 million. This deal is primarily focused on future net sales of the investigational medication tividenofusp alfa. This collaboration aims to advance the treatment opportunities for patients diagnosed with mucopolysaccharidosis type II (MPS II), otherwise known as Hunter syndrome.
About Tividenofusp Alfa
Tividenofusp alfa stands out as Denali's leading enzyme replacement therapy. It's designed specifically to address the symptoms associated with Hunter syndrome, which affects both cognitive and physical abilities. The Biologics License Application for accelerated approval of tividenofusp alfa is currently under the scrutiny of the U.S. Food and Drug Administration (FDA), with a target date for review set for later this year.
What the Leaders Are Saying
Ryan Watts, Ph.D., the Chief Executive Officer of Denali Therapeutics, expressed enthusiasm about this collaboration. He stated, "Partnering with Royalty Pharma really showcases the promising potential of tividenofusp alfa for the Hunter community. These additional funds will enable us to further our development programs as we prepare for the product's launch, which is critically important as we seek solutions for patients suffering from serious diseases.”
Pablo Legorreta, the CEO and Chairman of the Board at Royalty Pharma, echoed these sentiments, expressing delight in the collaboration. He emphasized the innovative nature of tividenofusp alfa, noting its potential to significantly address unmet medical needs in severe cognitive and physical impairments related to Hunter syndrome.
Transaction Details
The transaction includes specific conditions that need to be met, primarily the achievement of accelerated approval from the FDA for tividenofusp alfa. Upon closing the deal, Royalty Pharma is set to provide an initial payment of $200 million. Moreover, an additional payment of $75 million is contingent upon acquiring approval from the European Medicines Agency (EMA) before the end of 2029.
In return for their investment, Royalty Pharma will receive a 9.25% royalty on all worldwide net sales stemming from tividenofusp alfa produced by Denali. The royalty structure is designed to terminate when the payments reach a specified threshold, ensuring a balanced return on investment for both companies.
Advisors Involved
Denali Therapeutics engaged Gibson Dunn as their legal advisor, while Royalty Pharma was supported by Goodwin Procter and Maiwald as their legal counsel. This collaboration of expertise has contributed to a robust framework surrounding the agreement.
Who is Denali Therapeutics?
Denali is a pioneering biotechnology enterprise that focuses on developing biotherapeutics aimed at crossing the blood-brain barrier through its proprietary TransportVehicle platform. The company aspires to deliver effective treatments that transform the lives of individuals coping with neurodegenerative disorders and serious diseases linked to lysosomal storage.
Who is Royalty Pharma?
Founded in 1996, Royalty Pharma is a leader in acquiring biopharmaceutical royalties. They play a crucial role in funding innovation by collaborating with various entities in the biopharmaceutical landscape—from academic institutions to leading pharmaceutical companies. Their extensive portfolio includes both existing royalties from successful medications as well as participations in funding future breakthroughs through clinical trials.
Frequently Asked Questions
What is the focus of the funding agreement between Denali and Royalty Pharma?
The agreement centers on a $275 million royalty funding deal related to tividenofusp alfa, aiming to support its development for treating Hunter syndrome.
What is tividenofusp alfa?
Tividenofusp alfa is an investigational enzyme replacement therapy developed by Denali designed to treat symptoms of mucopolysaccharidosis type II, commonly known as Hunter syndrome.
What are the terms of the transaction?
The deal includes an initial payment of $200 million from Royalty Pharma and an additional $75 million tied to European approval for the treatment.
What is the potential impact of this collaboration?
This partnership can unlock new avenues for addressing serious unmet medical needs in the Hunter community and promote advancements in Denali's development pipeline.
How does Denali's technology work?
Denali utilizes a proprietary TransportVehicle platform designed to enhance the delivery of important therapeutics across the blood-brain barrier, targeting neurodegenerative conditions.
